TodayHealth & TechPennsylvania
A small trial helped some people with advanced retinitis pigmentosa sense light
Ten people with advanced retinitis pigmentosa received an experimental optogenetic injection plus special goggles. Some sensed light better. Normal vision did not return.

Read the original
The reporting lives at University of Pittsburgh. Our summary is checked against it, and we link it on every story.
The University of Pittsburgh reported on October 7, 2026, that a study published the same day in the New England Journal of Medicine tested an experimental optogenetic therapy in the PIONEER trial. Surgeons made one injection of a gene for the light-sensing protein ChrimsonR into retinal ganglion cells. The ten participants were legally blind from advanced retinitis pigmentosa and had little or no remaining vision. The protein works only with a camera, a processor, and goggles that project specific light patterns onto the retina.
Most eye-related side effects were mild or moderate, including temporary inflammation and short-lived rises in eye pressure. Seven of the ten people had improved light sensitivity, and six of those gains were large enough to count as clinically meaningful. The treatment did not restore normal vision or the ability to read. Some people could detect an object, tell where it was, and reach for it while wearing the goggles. EEG recordings led by Marlene Behrmann showed signals reaching the visual cortex. Four participants had consistent gains on real-world tasks over months to years of testing.
The trial is early and small. It is not a cure. GenSight Biologics, the company developing the approach, funded the work. Retinitis pigmentosa affects more than 1.5 million people worldwide and can stem from any of more than 100 genes. José-Alain Sahel of Pitt and UPMC is the first and co-corresponding author, with collaborators in Europe.
Health & Tech in PennsylvaniaPittsburgh, PennsylvaniaMedical researchVision careGood news on October 7
More good news
Other stories in the same neighborhood of kindness.
Health & TechA Penn Medicine van brings free eye disease screening to neighborhoods
Penn's Scheie Eye Institute in MOTION van screens people in underserved Philadelphia neighborhoods for glaucoma, diabetic retinopathy, and other conditions, with telehealth reads by ophthalmologists and donor-funded treatment for uninsured patients.
Verified · WHYY
Health & TechEpilepsy patients flagged their monitor and cut false alarms
In a small NIH-funded hospital study, 13 patients used a phone app to question their EEG monitor. False seizure alarms fell by about 80 percent. Larger outpatient trials are planned.
Verified · National Institutes of Health (NIH)
Health & TechDes Moines University and UnityPoint launch a rural health collaborative
Starting in Webster County, the effort targets earlier cancer screening, radon risk reduction, and an online hub of local resources.
Verified · KCRG